Market Expansion, Merger Agreements, Management Transitions, and Market Activity - Analyst Notes on Intuitive Surgical, Auxilium, Horizon Pharma, Tesaro and ArQule

NEW YORK, July 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Horizon Pharma, Inc. (NASDAQ: HZNP), Tesaro, Inc. (NASDAQ: TSRO) and ArQule Inc. (NASDAQ: ARQL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4352-100free.

--
Intuitive Surgical, Inc. Analyst Notes
On June 25, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced that its da Vinci Xi Surgical System has received a CE Mark, which allows the Company to market the system in Europe and other countries requiring CE mark. "We are pleased to bring the da Vinci Xi System to market in Europe and other countries that rely on the CE Mark for marketing authorization," said Henry Charlton, Intuitive Surgical Vice President, Sales and Marketing, Europe, Middle East, India and Africa (EMEIA), Latin America, Canada and Australia. "With the CE Mark, we're expanding our customer base that has access to this exciting new technology. The da Vinci Xi System represents the most advanced option available to date as we strive to make minimally invasive surgery the global standard of care." The da Vinci Xi System is an innovation of Intuitive Surgical that replaces large-incision open surgeries with a minimally invasive approach. The full analyst notes on Intuitive Surgical are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/ISRG/report.pdf

--
Auxilium Pharmaceuticals Inc. Analyst Notes
On June 26, 2014, Auxilium Pharmaceuticals Inc. (Auxilium) announced that it has entered into a definitive agreement with QLT Inc. (QLT), under which Auxilium will merge with QLT, a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products. Under the terms of the agreement, a wholly-owned subsidiary of QLT will be merged with and into Auxilium. QLT will remain incorporated in British Columbia, Canada, and will be named as "New Auxilium." The current shareholders of Auxilium will incur 3.1359 QLT shares for each Auxilium share, subject to certain adjustments. Adrian Adams, CEO and President of Auxilium, stated, "Building on Auxilium's strong foundation and commercial expertise, the merger with QLT represents a unique opportunity to accelerate our desired strategic transformation into a leading, diversified North American specialty biopharmaceutical company." The transaction is expected to drive shareholder value creation by accelerating Auxilium's ongoing transformation into a leading diversified North American specialty biopharmaceutical company. The full analyst notes on Auxilium are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/AUXL/report.pdf

--
Horizon Pharma, Inc. Analyst Notes
On June 18, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced the retirement of Robert J. De Vaere from his current position of Chief Financial Officer. His retirement will be effective on September 30, 2014. Further, the Company announced the appointment of Paul W. Hoelscher as Executive Vice President, Finance, effective June 23, 2014, and its Chief Financial Officer, effective October 1, 2014. Mr. Hoelscher joins Horizon from OfficeMax, Inc. where he most recently served as Senior Vice President, Finance and was co-lead in integration planning activities related to its recent merger with Office Depot. The full analyst notes on Horizon Pharma are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/HZNP/report.pdf

--
Tesaro, Inc. Analyst Notes
On June 27, 2014, Tesaro Inc.'s (Tesaro) stock increased 2.96% to end the day at $29.88, compared to the previous day's closing price at $29.02. The Company's stock grew 1.53% over the past three trading days, compared to the Nasdaq Composite which rose 1.09% during the same trading period. The full analyst notes on Tesaro are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/TSRO/report.pdf

--
ArQule Inc. Analyst Notes
On June 27, 2014, ArQule Inc. (ArQule) stock ended the day at $1.46 compared to the previous day's closing price at $1.42, representing a 2.82% growth. The Company's stock increased 4.29% over the past one trading month compared to the Nasdaq Composite which grew 3.80% during the same trading period. The full analyst notes on ArQule are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/ARQL/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED